0.001 (6.667%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company was founded in 2007 and is headquartered in Bundoora, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.04
Trade Value (12mth)
AU$6,658.00
1 week
0%
1 month
-16.67%
YTD
-40%
1 year
-37.5%
All time high
0.38
EPS 3 yr Growth
-54.20%
EBITDA Margin
N/A
Operating Cashflow
-$5m
Free Cash Flow Return
-261.00%
ROIC
-267.00%
Interest Coverage
-60.90
Quick Ratio
2.40
Shares on Issue (Fully Dilluted)
558m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
05 December 24 |
Notification regarding unquoted securities - 1AD
×
Notification regarding unquoted securities - 1AD |
|
05 December 24 |
Change of Director's Interest Notice (TO)
×
Change of Director's Interest Notice (TO) |
|
02 December 24 |
Presentation at ASCEPT, APFP & APSA Joint Congress
×
Presentation at ASCEPT, APFP & APSA Joint Congress |
|
21 November 24 |
Initial Director's Interest Notice X 2 (MB & IR)
×
Initial Director's Interest Notice X 2 (MB & IR) |
|
21 November 24 |
Final Director's Interest Notice (RP)
×
Final Director's Interest Notice (RP) |
|
21 November 24 |
Investor Presentation
×
Investor Presentation |
|
20 November 24 |
Chair address and CEO presentation to AGM
×
Chair address and CEO presentation to AGM |
|
20 November 24 |
Results of Meeting
×
Results of Meeting |
|
18 November 24 |
Board changes
×
Board changes |
|
05 November 24 |
Change in substantial holding
×
Change in substantial holding |
|
04 November 24 |
Application for quotation of securities - 1AD
×
Application for quotation of securities - 1AD |
|
04 November 24 |
Cleansing Notice under Section 708A
×
Cleansing Notice under Section 708A |
|
30 October 24 |
ASX Gems Investor Presentation
×
ASX Gems Investor Presentation |
|
24 October 24 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
|
23 October 24 |
Chief Medical Officer Appointments
×
Chief Medical Officer Appointments |
|
18 October 24 |
Letter to Shareholders, Notice of AGM & Proxy Form
×
Letter to Shareholders, Notice of AGM & Proxy Form |
|
10 October 24 |
AD-214 clinical advisory board
×
AD-214 clinical advisory board |
|
04 October 24 |
FY24 RDTI Refund Received $1.77m
×
FY24 RDTI Refund Received $1.77m |
|
10 September 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
|
05 September 24 |
Application for quotation of securities - 1AD
×
Application for quotation of securities - 1AD |
|
05 September 24 |
Cleansing Notice under Section 708A
×
Cleansing Notice under Section 708A |
|
02 September 24 |
Proposed issue of securities - 1AD
×
Proposed issue of securities - 1AD |
|
02 September 24 |
Transaction, investment facility update
×
Transaction, investment facility update |
|
30 August 24 |
Change in substantial holding
×
Change in substantial holding |
|
28 August 24 |
Preliminary Final Report
×
Preliminary Final Report |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
